BioSpace News Archive

Zynerba Pharmaceuticals, Inc. today announced the presentation of a poster at the 61st Annual Meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Ariz.

Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the publication of “Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells,” in Communications Biology.

PolyPid Ltd. today announced that Phase 2 clinical data for D-PLEX 100 will be highlighted in a podium presentation at the first triennial International Orthopaedic Trauma Association meeting being held on December 14-16, 2022, at the RAI Amsterdam Exhibition and Conference Center in Amsterdam, The Netherlands.

Milestone Pharmaceuticals Inc. today announced that members of the Company’s management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET.

Royal DSM, a global science-based company active in Health, Nutrition and Bioscience, comments on the findings from a recently published paper in Nature Medicine which reported that those infected with COVID-19 are at increased risk of long-term neurologic disorders that persist post infection.

Virios Therapeutics, Inc. today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022.

RaySearch announces a partnership with Leo Cancer Care in Great Britain for the development of a streamlined treatment planning solution for upright treatments.

Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10-year risk of death from a heart attack or stroke, stemming from atherosclerotic cardiovascular disease.

A review published recently in the international scientific journal Biomedicines highlights the therapeutic benefits of amniotic fluid in restoring, repairing and regenerating damaged tissue across a range of human diseases and disorders.

Today, Synexis ® , LLC announced the appointment of Dennis Doyle as the new chief executive officer (CEO) and James “Jimmy” Robert as its first chief commercial officer (CCO).